Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 29, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,258.83 pence per share.
- Treasury Holdings: 501,694,158 shares (representing 9.08% of total voting rights).
- Shares in Issue: 5,523,665,578 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 1,000,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 501,694,158. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,523,665,578) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (501,694,158) and its impact on total voting rights (9.08%).
- Note that this filing is a notification of a specific transaction and does not contain quarterly or annual financial results.